Clinical Trials Directory

Trials / Completed

CompletedNCT02794558

Safety and Effectiveness of MR Guided Focused Ultrasound Surgery in the Treatment of Early Breast Carcinomas

A Clinical Study To Evaluate the Safety and Effectiveness of MR Guided Focused Ultrasound Surgery in the Treatment of Early Breast Carcinomas

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
InSightec · Industry
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

Non-randomized, Single Arm Clinical study to Evaluate the Safety and Effectiveness of MR Guided Focused Ultrasound Surgery in the Treatment of Early Breast Carcinomas

Detailed description

Study specific aim is to Coagulate the tissue volume of a proven breast cancer with MRgFUS and Collect post treatment follow-up clinical and radiological data for a period of 5 years following MRgFUS for breast cancer. Safety of the treatment will be evaluated by recording and assessing the incidence and severity of device- related complications from the first visit through the 5 years follow-up period. Secondary objective of this study is to evaluate post treatment local recurrence in the same quadrant or less then 4cm from the periphery of the treated lesion, during a 5 year period following the MRgFUS treatment. Women with breast cancer in whom breast MR imaging identifies a single focal breast lesion up to 1.5 cm in diameter will be eligible for the study.

Conditions

Interventions

TypeNameDescription
DEVICEExAblate MRgFUSMR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed. Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment.

Timeline

Start date
2005-06-01
Primary completion
2019-03-01
Completion
2019-03-01
First posted
2016-06-09
Last updated
2019-07-01

Source: ClinicalTrials.gov record NCT02794558. Inclusion in this directory is not an endorsement.